Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic Cancer.
amyloid precursor-like protein 2
mouse model
pancreatic cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
28
02
2021
revised:
17
03
2021
accepted:
21
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
In the United States, pancreatic cancer is a major cause of cancer-related deaths. Although substantial efforts have been made to understand pancreatic cancer biology and improve therapeutic efficacy, patients still face a bleak chance of survival. A greater understanding of pancreatic cancer development and the identification of novel treatment targets are desperately needed. Our analysis of gene expression data from patient samples showed an increase in amyloid precursor-like protein 2 (APLP2) expression within primary tumor epithelium relative to pancreatic intraepithelial neoplasia (PanIN) epithelial cells. Augmented expression of APLP2 in primary tumors compared to adjacent stroma was also observed. Genetically engineered mouse models of spontaneous pancreatic ductal adenocarcinoma were used to investigate APLP2's role in cancer development. We found that APLP2 expression intensifies significantly during pancreatic cancer initiation and progression in the
Identifiants
pubmed: 33810510
pii: cancers13071535
doi: 10.3390/cancers13071535
pmc: PMC8036577
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : R21 CA223429
Pays : United States
Organisme : NIH HHS
ID : P50 CA127297
Pays : United States
Organisme : University of Nebraska Medical Center
ID : Graduate Studies Office Fellowships
Organisme : NCI NIH HHS
ID : P50 CA127297
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA223429
Pays : United States
Organisme : NIH HHS
ID : P30 CA036727
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009476
Pays : United States
Organisme : NIH HHS
ID : T32 CA009476
Pays : United States
Organisme : NIH HHS
ID : U54 GM115458
Pays : United States
Références
J Neurosci. 2000 Nov 1;20(21):7951-63
pubmed: 11050115
Front Mol Neurosci. 2017 Jan 20;9:161
pubmed: 28163673
Breast Cancer Res. 2004;6(5):R499-513
pubmed: 15318932
Gerontology. 1997;43(1-2):119-31
pubmed: 8996834
PLoS Genet. 2015 Aug 27;11(8):e1005432
pubmed: 26313004
Cancer Res. 2011 Mar 15;71(6):2318-27
pubmed: 21406403
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nature. 2011 Jun 15;474(7351):337-42
pubmed: 21677750
Cancer Biol Ther. 2013 Aug;14(8):752-60
pubmed: 23792571
Front Endocrinol (Lausanne). 2015 Jun 30;6:105
pubmed: 26175717
Exp Cell Res. 2006 Jul 1;312(11):1939-49
pubmed: 16584729
Clin Cancer Res. 2006 Sep 15;12(18):5277-87
pubmed: 17000660
Biol Chem. 2010 Sep;391(9):1019-29
pubmed: 20536387
Cancer Biol Ther. 2019;20(6):931-940
pubmed: 30810435
Gut. 2019 Jun;68(6):1034-1043
pubmed: 30658994
Invest Ophthalmol Vis Sci. 1998 Feb;39(2):292-300
pubmed: 9477985
Cancers (Basel). 2019 Jan 29;11(2):
pubmed: 30700038
FEBS Lett. 2013 Jun 27;587(13):2036-45
pubmed: 23707420
Eur J Neurosci. 2002 Sep;16(5):896-906
pubmed: 12372026
Br J Cancer. 2013 Jun 25;108(12):2590-600
pubmed: 23598299
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
FEBS Lett. 1999 Jan 8;442(1):95-8
pubmed: 9923612
Glia. 2019 Mar;67(3):525-538
pubmed: 30506868
Oncotarget. 2016 Apr 12;7(15):19430-44
pubmed: 26840089
Exp Cell Res. 2002 Nov 1;280(2):222-32
pubmed: 12413888
Int J Oncol. 2012 Oct;41(4):1464-74
pubmed: 22797723
J Pathol. 2008 Jun;215(2):155-63
pubmed: 18393365
J Biol Chem. 1999 Sep 17;274(38):27249-56
pubmed: 10480944
Oncotarget. 2015 Feb 10;6(4):2064-75
pubmed: 25576918
Nat Genet. 1993 Sep;5(1):95-100
pubmed: 8220435